戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  signature peptide as compared to undigested salmon calcitonin.
2                 Quantification of undigested salmon calcitonin, after solid-phase extraction from pla
3 yielded a more stable AMY(3)R, and human and salmon calcitonin agonists promoted AMY(3)R dissociation
4 ter incubation of sections with 125I-labeled salmon calcitonin and emulsion autoradiography.
5   Here, we present two crystal structures of salmon calcitonin-bound, GlcNAc-bearing CTR ECD at 1.78
6 ECD) in complex with a truncated analogue of salmon calcitonin ([BrPhe(22)]sCT(8-32)) has been determ
7 tion of LDTg amylin receptors by the agonist salmon calcitonin dose-dependently reduces body weight,
8               The molecular conformations of salmon calcitonin in aqueous solution have been investig
9 owing no degradative release of encapsulated salmon calcitonin in gastric conditions while yielding r
10 thacrylate crosslinker, a small polypeptide (salmon calcitonin) loads and releases up to 45 mug/mg hy
11 structures of receptors bound to rat amylin, salmon calcitonin or recently developed amylin-based pep
12                                              Salmon calcitonin (sCT) (20 to 100 ng/h) (1) increased t
13 )) and (Asp(17), Orn(21)) side-chain bridged salmon calcitonin (sCT) and hCT analogues.
14    Furthermore, the amylin and GLP-1 analogs salmon calcitonin (sCT) and liraglutide produce synergis
15 lation of all expressed receptors, decreased salmon calcitonin (sCT) binding affinities and signaling
16 ator or insertion into the disulfide bond of salmon calcitonin (sCT) demonstrates the utility for flu
17 ulin in vitro, and absorption enhancement of salmon calcitonin (sCT) in vivo.
18                                              Salmon calcitonin (sCT) is a drug which has been shown t
19                                              Salmon calcitonin (sCT) is an example of one of the many
20 dergo conjugation to the therapeutic peptide salmon calcitonin (sCT) via bridging of the Cys(1)-Cys(7
21  Tyr residues of both leucine enkephalin and salmon calcitonin (sCT) were targeted using appropriate
22                                  Reaction of salmon calcitonin (sCT) with 2,3-dibromomaleimide (1.1 e
23 inhibition of acylation of octreotide (Oct), salmon calcitonin (sCT), and human parathyroid hormone (
24 d demonstrate their capabilities in vivo for salmon calcitonin (sCT).
25 al delivery was explored for the delivery of salmon calcitonin (sCT).
26                     All three proteins bound salmon calcitonin (sCT).
27 te GAG interactions with the peptide hormone salmon calcitonin (sCT).
28 rials evaluating the effects of 200 IU nasal salmon calcitonin, six also used calcium supplements (to
29 les were tested in vitro with model proteins salmon calcitonin, urokinase, and rituximab to determine
30 s optimal performance for the small peptide, salmon calcitonin, whereas lower crosslinking density of
31 matically investigated with a small protein, salmon calcitonin, which could be analyzed both without
32 ded membranes that bound 125I-AC512 and 125I-salmon calcitonin with high affinity, but no high affini
33  used to synthesize a technetium-99m-labeled salmon calcitonin with the hynic-linked amino acid in pl